Cellcept and Myfortic Linked to Birth Defects and Fetal Loss Medical Video by Pharmacy

Cellcept and Myfortic Linked to Birth Defects and Fetal Loss

Pharmacy

Currently 0.00/5
1
2
3
4
5

Rating: 0.0 out of 0 votes

Comments (0)

You need to have the Flash Player installed and a browser with JavaScript support.

Description

FDA is advising healthcare professionals about an increased risk of fetal harm when women become pregnant while being treated with the immunosuppressant drugs Cellcept (mycophenolate mofetil) or Myfortic (mycophenolic acid) Myfortic is approved to prevent kidney transplant rejection. CellCept is approved to prevent heart, liver and kidney transplant rejection. These drugs are also sometimes used to treat immune-mediated conditions such as lupus and erythema multiforme, which are not approved ...